Literature DB >> 27749952

Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease.

Ralf Reilmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27749952     DOI： 10.1001/jamaneurol.2016.3916

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  5 in total

Review 1.  Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.

Authors:  Young-A Heo; Lesley J Scott
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 2.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

3.  Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

Authors:  Carey Wexler Sherman; Ravi Iyer; Victor Abler; Alexandria Antonelli; Noelle E Carlozzi
Journal:  Neuropsychol Rehabil       Date:  2019-03-08       Impact factor: 2.868

4.  Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's Disease.

Authors:  Shivaji A Thadke; J Dinithi R Perera; V M Hridya; Kirti Bhatt; Ashif Y Shaikh; Wei-Che Hsieh; Mengshen Chen; Chakicherla Gayathri; Roberto R Gil; Gordon S Rule; Arnab Mukherjee; Charles A Thornton; Danith H Ly
Journal:  Biochemistry       Date:  2018-03-27       Impact factor: 3.162

5.  Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?

Authors:  Filipe B Rodrigues; Gonçalo S Duarte; João Costa; Joaquim J Ferreira; Edward J Wild
Journal:  Mov Disord Clin Pract       Date:  2017-03-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.